Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer

被引：0
|
作者：
Martin Pölcher
Meike Eckhardt
Christoph Coch
Matthias Wolfgarten
Kirsten Kübler
Gunther Hartmann
Walther Kuhn
Christian Rudlowski
机构：
[1] University Hospital of Bonn,Department of Gynecology and Obstetrics, Center for Integrated Oncology, Bonn University Medical Center
[2] University Hospital of Bonn,Institute of Clinical Chemistry and Pharmacology, Center for Integrated Oncology
来源：
Cancer Chemotherapy and Pharmacology | 2010年 / 66卷
关键词：
Sorafenib; Ovarian cancer; Neoadjuvant chemotherapy; Carboplatin; Paclitaxel;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：203 / 207
页数：4
相关论文
共 50 条
  • [1] Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer
    Poelcher, Martin
    Eckhardt, Meike
    Coch, Christoph
    Wolfgarten, Matthias
    Kuebler, Kirsten
    Hartmann, Gunther
    Kuhn, Walther
    Rudlowski, Christian
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (01) : 203 - 207
  • [2] Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer
    Watanabe, M
    Aoki, Y
    Tomita, M
    Sato, T
    Takaki, Y
    Kato, N
    Kikuchi, M
    Kase, H
    Tanaka, K
    GYNECOLOGIC ONCOLOGY, 2002, 84 (02) : 335 - 338
  • [3] Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer
    Ozols, RF
    SEMINARS IN ONCOLOGY, 2000, 27 (03) : 3 - 7
  • [4] Tolerance of weekly paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
    Dessai, S. B.
    Chakraborty, S.
    Babu, T. V. S.
    Nayanar, S.
    Bhattacharjee, A.
    Jones, J.
    Balasubramanian, S.
    Patil, V. M.
    INDIAN JOURNAL OF CANCER, 2016, 53 (02) : 280 - 283
  • [5] Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
    Tao, Yin
    Tang, Xue-Ting
    Li, Xing
    Wu, An-Shan
    Zhou, Hou-Shen
    Zhou, Cheng-fang
    FRONTIERS IN MEDICINE, 2022, 9
  • [6] Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
    Dessai, S. B.
    Chakraborty, S.
    Babu, T. V. S.
    Nayanar, S.
    Bhattacharjee, A.
    Jones, J.
    Balasubramanian, S.
    Patil, Vijay M.
    SOUTH ASIAN JOURNAL OF CANCER, 2016, 5 (02) : 63 - +
  • [7] Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer
    Kim, Yoo-Na
    Lee, Yong Jae
    Lee, Jung-Yun
    Nam, Eun Ji
    Kim, Sang Wun
    Kim, Sunghoon
    Kim, Young Tae
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2020, 31 (02)
  • [8] Combination Chemotherapy with Carboplatin and Paclitaxel for Advanced Thymic Cancer
    Furugen, Makoto
    Sekine, Ikuo
    Tsuta, Koji
    Horinouchi, Hidehito
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Kubota, Kaoru
    Tamura, Tomohide
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (08) : 1013 - 1016
  • [9] Phase Ib study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
    Broekman, K. E.
    Reyners, A. K. L.
    Touw, D. J.
    Hof, M. A. J.
    Jalving, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 354 - 354
  • [10] Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
    K. Esther Broekman
    Marieke A. J. Hof
    Daan J. Touw
    Jourik A. Gietema
    Hans W. Nijman
    Joop D. Lefrandt
    An K. L. Reyners
    Mathilde Jalving
    Investigational New Drugs, 2020, 38 : 1454 - 1462
12345